Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.

Ayoub, Fares; Odenwald, Matthew; Micic, Dejan; Dalal, Sushila R; Pekow, Joel; Cohen, Russell D; Rubin, David T; Sakuraba, Atsushi

Ayoub, Fares; Odenwald, Matthew; Micic, Dejan; Dalal, Sushila R; Pekow, Joel; Cohen, Russell D; Rubin, David T; Sakuraba, Atsushi.

Affiliation

Ayoub F; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Odenwald M; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Micic D; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Dalal SR; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Pekow J; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Cohen RD; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Rubin DT; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.
Sakuraba A; Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA.

Intest Res ; 20(2): 240-250, 2022 Apr.

Article in En | MEDLINE | ID: mdl-35124951

Key words

Crohn disease; Meta-analysis; Perianal disease; Perianal fistula; Vedolizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Systematic_reviews Language: En Journal: Intest Res Year: 2022 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google